Treatment for mood and anxiety disorders:
quetiapine and aripiprazole

Sajatovic M.
Department of Psychiatry,
Case Western Reserve University,
School of Medicine,
10900 Euclid Avenue,
Cleveland, OH 44106, USA.
Curr Psychiatry Rep. 2003 Aug;5(4):320-6


Atypical antipsychotic agents have a broad range of therapeutic efficacy, a relatively low incidence of causing extrapyramidal adverse effects, and a low tardive dyskinesia profile. This has led to very rapid growth in the use of these compounds as broad-spectrum psychotropic agents, and it has been reported that more than 70% of prescriptions for atypical antipsychotic medications are being used for conditions other than schizophrenia. In the area of bipolar disorder, in particular, atypical antipsychotic agents appear to positively affect illness outcome, and are considered potential first-line treatment agents. Quetiapine was approved by the US Food and Drug Administration in 1997, and is currently marketed in the US to treat schizophrenia. Aripiprazole was recently approved for the treatment of schizophrenia by the US Food and Drug Administration in late 2002, and is being used increasingly in clinical settings. Recent reports suggest that quetiapine and aripiprazole are valuable additions to the psychotropic armamentarium for the treatment of mood and anxiety disorders. Data from clinical trials and clinical reports are discussed herewith.
Bipolar disorders
Quetiapine: efficacy
The manic spectrum
Quetiapine (Seroquel)
Drug-induced weight gain
Aripiprazole (Abilify, Abilitat)
Bipolar treatment guidelines
Gabapentin, pain and depression
Atypical neuroleptics for bipolars
Quetiapine and the sound of music
Quetiapine (Seroquel) for bipolar disorder

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family